Skip to content
Screener
Serina Therapeutics logo

Serina Therapeutics

SER

Serina Therapeutics is a clinical-stage biotechnology company focused on developing a pipeline of drug candidates for neurological diseases using its proprietary POZ drug delivery platform.

Market cap
$36.32M-14.3%

Earnings

Next report

Date not yet announced

Competitors

Profile

Serina Therapeutics is a clinical-stage biotechnology company focused on developing a pipeline of drug candidates for neurological diseases using its proprietary POZ drug delivery platform. The POZ technology utilizes a synthetic, water-soluble polymer called poly(2-oxazoline) to improve the efficacy and safety profiles of small molecules, RNA-based therapeutics, and antibody-drug conjugates. By enabling precise control over drug loading and release, the company aims to provide continuous drug delivery through easy-to-administer subcutaneous injections.

Competitive position

Serina is a pioneer in poly(2-oxazoline) polymer technology, positioning itself as a superior alternative to traditional PEG-based delivery systems.

GeographiesUnited States
Customer segmentsPharmaceutical companies, Healthcare providers, Patients
Business modelR&D, Licensing, IP-heavy
SuppliersRaw material suppliers for 2-ethyl 2-oxazoline, Contract manufacturing organizations, Clinical research organizations
CustomersPharmaceutical partners, Specialty pharmacies, Hospitals and clinics
Listed2024
CEOSteven A. Ledger
FilingsSEC EDGAR

FAQ

What is Serina Therapeutics's market cap?
Serina Therapeutics (SER) has a market capitalization of $36.3M and trades on AMEX.
Who are Serina Therapeutics's competitors?
Serina Therapeutics's key competitors include Supernus Pharmaceuticals, AbbVie, Gain Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Serina Therapeutics partner with?
Serina Therapeutics's notable partners include Pfizer, BioNTech, Moderna.
Where is Serina Therapeutics headquartered?
Serina Therapeutics is headquartered in United States of America. It has been publicly traded since 2024.